• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

Expanded indication for MS treatment granted


Interferon beta-1b (Betaseron, Berlex) can now be prescribed to patients with multiple sclerosis who have experienced a first clinical episode and have MRI features consistent with MS. The new approval was based on findings from BENEFIT, a study of patients experiencing their first clinical demyelinating event. Results showed the drug delayed time to a second event by one year compared with placebo. Betaseron is also indicated for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.